^
    1d
    Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Jan 2027 --> Dec 2025
    Trial primary completion date
    |
    Mektovi (binimetinib) • Beleodaq (belinostat)
    14d
    Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework. (PubMed, Biomed Chromatogr)
    Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC-MS/MS, HPLC-UV, FTIR, TLC, NMR, and ESI-MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug-drug interactions.
    Review • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    Beleodaq (belinostat)
    26d
    ETCTN 10500: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment (clinicaltrials.gov)
    P1, N=48, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    RAS wild-type • EZH2 mutation
    |
    Tazverik (tazemetostat) • Beleodaq (belinostat)
    28d
    Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma (clinicaltrials.gov)
    P2, N=15, Completed, University of Miami | Active, not recruiting --> Completed
    Trial completion
    |
    IFNA1 (Interferon Alpha 1)
    |
    cyclophosphamide • Beleodaq (belinostat)
    29d
    ETCTN: Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2027
    Trial completion date
    |
    Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)
    2ms
    RESOLVE: Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)
    3ms
    Comprehensive Analysis to Reveal Nitrogen Metabolism-Associated Genes as a Prognostic Index in Head and Neck Squamous Cell Cancer. (PubMed, Curr Med Chem)
    Our study established a NM-related gene signature closely linked to immune microenvironment and drug sensitivity, highlighting potential biomarkers and therapeutic targets for prognosis and personalized therapy in HNSCC.
    Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1)
    |
    erlotinib • gefitinib • Beleodaq (belinostat)
    5ms
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)
    5ms
    Establishment of a prognostic model and immune profiling based on phagocytic regulatory genes in hepatocellular carcinoma. (PubMed, Transl Cancer Res)
    Regarding treatment, Belinostat, Dabrafenib, and Sorafenib showed higher sensitivity in the low-risk group, whereas Docetaxel demonstrated greater sensitivity in the high-risk category. This study offers a comprehensive analysis of the immune landscape characteristics and potential anticancer drugs in HCC based on PFRGs, providing valuable insights and novel perspectives for the treatment of HCC patients.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • NKG2D (killer cell lectin like receptor K1)
    |
    Tafinlar (dabrafenib) • sorafenib • docetaxel • Beleodaq (belinostat)
    6ms
    Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization. (PubMed, Adv Mater)
    To target these epigenetic vulnerabilities, innovative carrier-free nano-epidrugs (siMBD-R NPs) are developed, incorporating first-line doxorubicin (DOX) with siRNA against METTL1 (siMETTL1), FDA-approved HDAC inhibitor belinostat (BEL), and DSPE-PEG2000-cRGD. In vivo studies demonstrate that siMBD-R NPs can significantly potentiate chemosensitivity, achieving an 81.5% relative increase in tumor inhibition, and can activate an immune response. This work highlights the potential benefits of leveraging dual-targeted epigenetic intervention to evoke osteosarcoma chemosensitization.
    Journal
    |
    HDAC1 (Histone Deacetylase 1) • METTL1 (Methyltransferase 1, TRNA Methylguanosine)
    |
    doxorubicin hydrochloride • Beleodaq (belinostat)
    6ms
    Methylation-induced suppression of YAP/TAZ confers sensitivity to HDAC inhibitors in high grade IDH mutant gliomas. (PubMed, JCI Insight)
    Finally, belinostat extended in vivo survival only in IDHmut glioma models, not in IDHmut GBM models. Our findings provide a mechanistic rationale for further studies of HDACi in IDHmut glioma patients, as well as the potential use of YAP/TAZ as a biomarker of HDACi sensitivity in cancers.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • TAFAZZIN (Tafazzin)
    |
    IDH wild-type
    |
    Beleodaq (belinostat)
    6ms
    Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | N=32 --> 7 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    Mektovi (binimetinib) • Beleodaq (belinostat)